Dr. Chen Xiaobo, PhD, from Ussure Life Science, is honored as a member of the World Productivity Academy, promoting innovation in the biotechnology industry and gaining international recognition

Recently, Dr. Chen Xiaobo, Chief Scientist of Yousai Life Science Development Co., Ltd., was officially awarded the title of Academician by the World Academy of Productivity Science, in recognition of his outstanding contributions to the global productivity improvement through cutting-edge technology research and industrial application in the field of life sciences. This honor not only represents a high recognition of Dr. Chen Xiaobo's personal scientific achievements but also signifies the continuous deepening influence of China's biotechnology enterprises on the international innovation stage.

The World Productivity Academy (WAPS) is an important part of the World Productivity Science Alliance (WCPS). Founded in 1969, the WCPS aims to promote productivity across all sectors of the national economy, improve work quality, and enhance living standards, thereby creating world peace and prosperity through productivity advancements. This award marks the entry of China's biotechnology talents into the ranks of the world's top scientific research. With continuous breakthroughs by innovative entities such as Ussay Life Sciences, China is transitioning from a participant in the global bioeconomy to a rule-maker. Industry experts predict that the subsequent research achievements of Academician Chen Xiaobo's team may reshape the international industrial landscape in fields such as medicine, energy, and materials.

Introduction of Dr. Chen Xiaobo  

Scholarly Essence·Scientific research for the benefit of the country

Chen Xiaobo, a male researcher born in August 1975 in Heilongjiang Province, is a member of the China Zhi Gong Party. He earned his MD and completed postdoctoral training at Heidelberg University in Germany, where he worked under a world-class research team specializing in vascular regeneration and stem cell research. After obtaining his Master of Clinical Medicine from Nankai University in 1998, he pursued advanced studies in Germany. During his tenure at the Max Planck Institute for Cardiovascular Research (MPI), he overcame the challenge of establishing models for lower limb ischemia and myocardial ischemia, developing an internationally leading cellular hypoxia research system. His groundbreaking work, published in top-tier journals including *Circulation*, earned him the Max Planck Institute's Outstanding Research Award.

National Outstanding Individual for Overseas Chinese and Their Families; National Outstanding Member of the China Zhi Gong Party; National Social Service Advanced Individual of the China Zhi Gong Party Central Committee; National Advanced Individual for Rural Revitalization Targeted Assistance of the China Zhi Gong Party Central Committee; Shanghai Lianxiang Public Welfare Fund Public Welfare Star; First-tier Talent in Tianjin's "131" Innovative Talent Cultivation Program; Outstanding Entrepreneur in Tianjin's "111" Entrepreneur Team Project; Leading Talent in Innovation and Entrepreneurship of Binhai New Area; Overseas High-Level Returned Scholars of Binhai High-tech Zone

In 1998, Chen Xiaobo earned his Master's degree in Clinical Medicine from Nankai University and was subsequently sent on a government-sponsored scholarship to Heidelberg University in Germany. During his doctoral studies there, he mastered both in vivo and in vitro vascular regeneration research methodologies. He independently developed animal models for lower limb ischemia, myocardial ischemia, and vascular regeneration, while establishing cellular hypoxia and injury models. Utilizing primary cultured vascular endothelial cells, vascular smooth muscle cells, endothelial progenitor cells, and mouse/rat animal models, he conducted comprehensive in vivo and in vitro studies on vascular regeneration. As the director of the vascular regeneration research laboratory, he oversaw doctoral student supervision and published multiple high-impact research papers.

After graduating from Heidelberg University, Chen Xiaobo joined the Max Planck Institute in Germany, where he became a senior researcher and received the Max Planck Prize. The Max Planck Institute comprises over 80 research institutes, covering fundamental research in natural sciences, life sciences, social sciences, arts, and humanities. Its achievements in these fields are world-renowned, making it the dream research institution for many scientists.

After returning to China, Dr. Chen Xiaobo served as executive and technical director at multiple listed companies. He founded Yousai Life Science Development Co., Ltd., successfully commercializing various biological cell products. Leading the R&D center, he established comprehensive laboratory technologies for adipose mesenchymal stem cell (adipose MSC) isolation, cultivation, expansion, and storage. Building on this foundation, he conducted large-scale expansion cultivation research, achieving significant scientific breakthroughs. Dr. Chen spearheaded the development of extraction protocols for adipose MSCs from mouse, rat, and adult surgical fat samples, as well as liposuction fat. He also utilized these technologies in animal studies for autologous transplantation therapy in myocardial infarction patients. Furthermore, he perfected cell therapy techniques for isolating mononuclear cells from adult peripheral blood and umbilical cord blood to expand CIK cells, with these technologies being applied in tumor patients' cellular immunotherapy. During this period, he completed the commercialization of immunotherapy technologies including immune cells, mesenchymal stem cells, CAR-T, and TILS. Dr. Chen also led multiple domestic and international research projects, including the establishment of Tianjin Key Enterprise Laboratories, postdoctoral workstations, and the Beijing-Tianjin-Hebei Institute City Project.

In the field of industrial innovation, Dr. Chen Xiaobo established the GMP-certified Yousai Life Cell Preparation Laboratory, which has successfully obtained third-party accreditation. He also developed a B+A-grade clean production R&D center and built a 3,000-square-meter coastal biological cell resource storage facility with a capacity of 3 million samples.

After returning to China, Dr. Chen Xiaobo devoted himself to public science education. Leveraging frontline data from his laboratory and modern digital science communication methods, he established a 1,000-square-meter Biological Cell Life Science Museum. Designated as Tianjin's Science Education Base, Industrial Tourism Scenic Area, Anatomical Society Science Education Base, and Nankai University Medical School Innovation Science Education Base, the facility educates diverse age groups, attracting over 20,000 visitors annually. It has hosted more than 30 regional science outreach events, including educational campaigns, Party-building activities, and the "Upward, Youngsters!" program from the converged media center. The museum frequently welcomed students from Shanjiutou Hope Primary School and Baijiayu Primary School in Hebei's Fuping County, revolutionary base areas, fostering their scientific spirit of patriotism and knowledge-driven development. Since 2020, he has donated to underprivileged students in Yanshan County, Panzhihua for three consecutive years. In 2021, he funded track renovations at Hangu Salt Field Primary School and partnered with Shanghai Lianxiang Public Welfare Fund, donating over 120,000 yuan annually for charitable causes. When Typhoon Doksuri moved north in 2023, triggering unprecedented heavy rainfall across Hebei, Beijing, and Tianjin, the Beijing-Tianjin-Hebei flood control system faced severe challenges. Dr. Chen led Yousai Life to donate 60,000 yuan worth of relief supplies. In December 2023, a 6.2-magnitude earthquake struck Jishishan County, Linxia Prefecture, Gansu Province, causing massive casualties. Dr. Chen Xiaobo promptly donated supplies worth 15,000 yuan to Jishishan County. In 2024, Jiang Zuojun, Vice Chairman of the National Committee of the Chinese People's Political Consultative Conference (CPPCC) and Chairman of the Central Committee of the China Zhi Gong Party, led a delegation to Bijie City, Guizhou Province, to conduct research on targeted assistance to Qixingguan District and the "region + sector" collaborative assistance program for Bijie. During the visit, Jiang and his team toured a mental health room funded by Dr. Chen Xiaobo, who is a member of the Social Service Committee of the Central Committee of the China Zhi Gong Party and Executive President of Yousai Life Science Development Co., Ltd., and listened to a staff briefing.

In the realm of policy advocacy, Dr. Chen Xiaobo has actively leveraged his industrial expertise to submit multiple proposals and recommendations through the CPPCC platform. His submissions, including "Proposal on Clinical Stem Cell Therapy,"  "Proposal for Establishing a Cell Industry Promotion Center,"  "Reflections on COVID-19 Prevention and Economic Development in the Post-Pandemic Era,"  "Enhancing the Cell Industry in Binhai New Area to Facilitate High-Quality Development," and "Prevention and Control of Long COVID in the Post-Pandemic Era," have received recognition from CPPCC leadership. Several of these proposals have been implemented into policies, making significant contributions to the high-quality development of the city's biocell industry.

2024 Award for Outstanding Individuals in the Targeted Assistance Program for Rural Revitalization by the Central Committee of the China Zhi Gong Party.

In April 2024, a clinical trial for treating advanced liver cancer using autologous tumor-infiltrating lymphocytes (TILs) in collaboration with Academician Wang Fusheng's team at the General Hospital of the People's Liberation Army was officially approved, following prior ethical review. The therapy achieved a 60% overall response rate during its pilot phase.

In 2024, Dr. Chen Xiaobo was elected Vice President of the First Council of the Overseas Chinese Chamber of Commerce in Binhai New Area.

In 2023, the Tianjin Municipal Committee of the China Zhi Gong Party and its members were honored for their participation in the central government's targeted rural revitalization assistance program. Dr. Chen Xiaobo from Ussay Life was awarded the title of Outstanding Individual.

In November 2023, the Binhai New Area Intellectuals Association held its inaugural meeting, where Dr. Chen Xiaobo was elected Vice President of the Third Council.

In 2023, Dr. Chen Xiaobo was elected as the Director of the Biomedical Technology Committee at Tianjin Overseas Chinese Chamber of Commerce, while Yousai Life continued to support public welfare initiatives.

In 2023, Dr. Chen Xiaobo was named one of the National Outstanding Individuals of Returned Overseas Chinese and Their Families.

In September 2023, the Tianjin Cell and Gene Therapy Innovation Consortium was jointly established by Haihe Laboratory of Cell Ecology and Yousai Life Science Development Co., Ltd.

In June 2023, the final of the 4th Tianjin 'Haihe Talent' Innovation and Entrepreneurship Competition (Postdoctoral Innovation and Entrepreneurship Division) and the 2nd National Postdoctoral Innovation and Entrepreneurship Competition (Tianjin Division) was held in Binhai New Area.

The Tianjin competition attracted nearly 2,000 participants with 373 registered innovation and entrepreneurship projects, ranking among the nation's top in terms of registration scale. After preliminary rounds, 85 innovation projects and 75 entrepreneurship projects advanced to the finals. The event also awarded plaques to 30 newly recognized postdoctoral research stations in the new district, including You Sai Life Science Development Co., Ltd.

In May 2023, Dr. Chen Xiaobo, Executive President of Yousai Life, was named a Public Welfare Star by the Shanghai Lianxiang Public Welfare Foundation.

In 2022, Dr. Chen Xiaobo, Executive President of Yousai Life Science Development Co., Ltd., was honored as an Outstanding Individual in Social Service Work by the China Zhi Gong Party.

In 2023, the You Sai Life Science Experience Center was officially designated as a 'Tianjin Science Education Base'.

In December 2022, Yousai Life was honored with the title of "National High-tech Enterprise".

In November 2022, Chen Xiaobo, Executive President of Yousai Life Science Development Co., Ltd. and member of the Binhai New Area Committee of the China Zhi Gong Party, commissioned the Panzhihua Municipal Committee of the same party to donate 15,000 RMB in one-year school living allowances to 10 underprivileged students at Yongxing Town Central School in Yanbian County.

In 2022, the list of experts in the intellectual property database of Binhai New Area was released, with Dr. Chen Xiaobo making the list.

In the same period, it was awarded the title of National High-Tech Enterprise, selected as a core participant in Tianjin Cell Valley, included in the National MIIT Jing-Jin-Ji Life Health Industry Cluster, and certified as a Tianjin Specialized, Refined, Distinctive and Innovative Enterprise by the Municipal Industry and Information Technology Bureau.

In October 2022, we established a joint innovation and entrepreneurship practice base with Nankai University School of Medicine, further deepening university-enterprise collaboration. This initiative fosters close alignment in medical technology services, research platform development, teaching-research reforms, and medical talent cultivation, promoting comprehensive, multi-dimensional, and end-to-end integration between both parties.

During the same period, the company partnered with the Tianjin and Shenzhen Institutes of CAS Advanced Institute to establish a stem cell technology transfer base, and successfully secured funding for the 'Beijing-Tianjin-Hebei Mesenchymal Stem Cell Clinical Collaborative Innovation Project'.

On October 9, 2022, the Beijing-Tianjin-Hebei Collaborative Innovation Project and the Academy-City Cooperation Project, jointly proposed by the Institute of Advanced Technology of the Chinese Academy of Sciences and Yousai Life Science Development Co., Ltd., were officially approved and announced for public notice.

On February 5, 2024, the quality recheck project of China Institute for Food and Drug Control for the stem cell preparation product of Ussure Life was successfully completed, marking a new stage in the development of Ussure Life's cell-based drugs.

On November 3, 2024, the 'TILS Cell Therapy Application Project' by Yousai Life Science Development Co., Ltd. was recognized as a model innovation case by the Tianjin Association for Science and Technology.

On October 28,2024, Dr. Chen Xiaobo was honored with the title of Outstanding Member of the China Zhi Gong Party.

In February 2025, Dr. Chen Xiaobo was honored as an Outstanding Contributor to the Central Committee of China Zhi Gong Party's Rural Revitalization Targeted Assistance Program.

In May 2025, I participated in the development of the group standard "Technical Requirements for the Application of Cellular Microvesicle Aerosol Inhalation Therapy in Respiratory Disease Treatment". Comrades including Chen Xiaobo served as lead drafters, making significant contributions to the standardization process.

In June 2025, Yousai Life was honored as a Star-Rising Enterprise for Service Industry Innovation and Development in Tianjin.

In terms of collaboration with healthcare platforms:

The company has established a clinical treatment research center through a four-party collaboration with Tianjin Medical University, Aerospace Center Hospital, and the Fifth Medical Center of the General Hospital of the Chinese People's Liberation Army.

The company has established a collaboration with Tianjin Medical University General Hospital on the development of mesenchymal stem cell exosomes and cell-based drugs, and with Nankai University School of Medicine on a rapid in vitro differentiation protocol for adipose-derived stem cells into insulin-secreting cells.

The company cooperates with Tianjin Medical University General Hospital

Mesenchymal Stem Cell Drug Development Center;

Mesenchymal Stem Cell Exosome Clinical Application Center; 3. Diabetes Cell Drug Research Center;

4.Mechanism Research on Umbilical Cord Mesenchymal Stem Cells for Treating Diabetic Erectile Dysfunction;

5. Mechanism Research on Umbilical Cord Blood Mesenchymal Stem Cell Exosomes Regulating Mitochondrial Dynamics via Nrf2 Pathway to Improve Sepsis-Induced Myocardial Injury.

The company collaborates with the Fifth Medical Center of the General Hospital of the Chinese People's Liberation Army, Tianjin Medical University, and Aerospace Center Hospital, among others.

Clinical Research Center for Cell Therapy;

Radiofrequency ablation combined with local injection of DC-CIK cells and PD-1 therapy for multiple nodular hepatocellular carcinoma;

Tumor-infiltrating lymphocyte (TIL) interventional therapy for hepatocellular carcinoma;

4. Cryopreservation of allogeneic umbilical cord mesenchymal stem cells for treatment of moderate to severe hepatic injury and liver failure.

The company has collaborated with the Chinese Academy of Sciences on the Beijing-Tianjin-Hebei Mesenchymal Stem Cell Clinical Collaborative Innovation Project, and with the Chinese Academy of Engineering on the development of a full-process technology for tumor-infiltrating lymphocytes and its therapeutic effects in malignant solid tumors.

The company conducted a single-arm exploratory clinical study with the Chinese Academy of Medical Sciences Blood Disease Hospital to evaluate the safety and efficacy of allogeneic umbilical cord-derived mesenchymal stem cells in treating hematologic malignancies with long-term blood cell reduction following CAR-T therapy.

The journey ahead·Exploration of life

In 2025, Yousai Life Cell Therapy passed the quality review by the National Institutes for Food and Drug Control (NIFDC), with its TILS treatment program recognized as a model innovation in Tianjin. Dr. Chen Xiaobo is leading his team to pioneer cutting-edge research in diabetes cell therapy and sepsis-induced myocardial repair, steadfastly fulfilling the mission of 'making cell technology accessible to all for human health.'